Francesca Panko
Adult Health · Stuart, FLNPI 1639603830
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Boehringer Ingelheim at 58.2% of the total. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 433 payments — averaging $47.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$12K
- AstraZeneca$2K
- GSK$707
- Actelion Pharmaceuticals US, Inc.$602
- Amgen$556
- United Therapeutics Corporation$541
- plus $4K from 31 others
What the payments were for
- Speaking & faculty fees$9,16045%
- Travel & lodging$9104%
- Food & beverage$10,40051%
- Education$800%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 81 | $11,964 |
| AstraZeneca | 75 | $2,082 |
| GSK | 40 | $707 |
| Actelion Pharmaceuticals US, Inc. | 19 | $602 |
| Amgen | 15 | $556 |
| United Therapeutics Corporation | 12 | $541 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $536 |
| Insmed, Inc. | 21 | $512 |
| Inogen, Inc. | 24 | $323 |
| Philips North America LLC | 12 | $279 |
| Regeneron Healthcare Solutions, Inc. | 8 | $227 |
| Pulmonx Corporation | 6 | $225 |
| Mylan Specialty L.p. | 10 | $191 |
| Grifols USA, LLC | 10 | $164 |
| Baxter Healthcare | 10 | $163 |
| Advanced Respiratory, Inc | 6 | $153 |
| Mallinckrodt Hospital Products Inc. | 7 | $150 |
| Novartis | 6 | $138 |
| Verona Pharma, Inc. | 5 | $129 |
| Pfizer | 6 | $125 |
| Paratek Pharmaceuticals, Inc. | 7 | $117 |
| Sanofi | 5 | $107 |
| Electromed, Inc. | 9 | $99 |
| Merck | 3 | $84 |
| Vifor Pharma, Inc. | 2 | $51 |
| Johnson & Johnson | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $22 |
| Melinta Therapeutics, LLC | 1 | $22 |
| Olympus America Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Novo Nordisk | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$392
- FASENRA$372
- OFEV$264
- CHARTIS CATHETER$137
- ZEPHYR DELIVERY CATHETER$137
- ZEPHYR ENDOBRONCHIAL VALVE$137
- PULMONX CHARTIS TABLET CONSOLE$137
- BREZTRI$129
- NUCALA$125
- UPTRAVI$125
- OPSUMIT$125
- TYVASO$112
- AIRSUPRA$104
How this compares
$20,551 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 306 | $250,312 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $246,504 |
| OfevNintedanib Esylate | 14 | $181,668 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 100 | $84,952 |
| Breo ElliptaFluticasone/Vilanterol | 98 | $39,190 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $30,614 |
| Spiriva RespimatTiotropium Bromide | 43 | $28,901 |
| EliquisApixaban | 34 | $23,827 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $15,060 |
| Bosentan | 11 | $13,690 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 56 | $10,756 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,445 |
| Arnuity ElliptaFluticasone Furoate | 30 | $8,871 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $6,766 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 148 | $4,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $707 | $313,434466 claims |
| Grifols USA, LLCProlastin C | $164 | $246,50413 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $11,964 | $241,184111 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,082 | $95,396133 claims |
| PfizerEliquis | $125 | $23,82734 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $602 | $13,69011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Stuart
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Cynthia OteroMaitland$31K
- Jennifer GodshallTampa$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.